These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18424866)

  • 1. Clinical practice guideline for cardiovascular risk management in the Netherlands.
    Smulders YM; Burgers JS; Scheltens T; van Hout BA; Wiersma T; Simoons ML;
    Neth J Med; 2008 Apr; 66(4):169-74. PubMed ID: 18424866
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cardiovascular disease: an evidence-based clinical aid.
    Cradick NH
    Med J Aust; 2004 Feb; 180(4):197-8; author reply 198. PubMed ID: 14960146
    [No Abstract]   [Full Text] [Related]  

  • 4. Living up to 100 years of Bayer Healthcare cardiovascular protection - Bayer Healthcare Cardiovascular : 20 years of participation in the South African cardiovascular community.
    Cardiovasc J Afr; 2009; 20(1):91-4. PubMed ID: 19287826
    [No Abstract]   [Full Text] [Related]  

  • 5. The management of hypertension.
    Simpson FO
    N Z Med J; 1995 May; 108(1000):206. PubMed ID: 7783991
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular risk: who should we treat, and how much should we stratify?
    Patel A
    Heart; 2009 May; 95(10):783-4. PubMed ID: 19131441
    [No Abstract]   [Full Text] [Related]  

  • 7. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
    Tsang JL; Mendelsohn A; Tan MK; Hackam DG; Leiter LA; Fitchett D; Lin PJ; Grima E; Langer A; Goodman SG;
    Am J Cardiol; 2008 Nov; 102(9):1142-5. PubMed ID: 18940280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A polypill for secondary prevention: time to move from intellectual debate to action.
    Fuster V; Sanz G
    Nat Clin Pract Cardiovasc Med; 2007 Apr; 4(4):173. PubMed ID: 17380163
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
    Hobson A; Curzen N
    Thromb Haemost; 2009 Jan; 101(1):23-30. PubMed ID: 19132185
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cardiovascular and metabolic diseases. Imidazolin-antagonists and the sympathetic nervous system].
    Z Kardiol; 1998 Oct; 87(10 Suppl):1-4. PubMed ID: 9835010
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy.
    Khakoo AY; Yeh ET
    Nat Clin Pract Oncol; 2008 Nov; 5(11):655-67. PubMed ID: 18797437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Time for a European perspective on cardiovascular prevention].
    Nilsson PM; Perk J; Rydén L
    Lakartidningen; 2008 Apr 2-8; 105(14):1000-4. PubMed ID: 18478749
    [No Abstract]   [Full Text] [Related]  

  • 13. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
    Sirois C; Poirier P; Moisan J; Grégoire JP
    Int J Cardiol; 2008 Sep; 129(2):172-9. PubMed ID: 18495263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hope for the future: early recognition of increased cardiovascular risk in children and how to deal with it.
    Masi S; Charakida M; Wang G; O'Neill F; Taddei S; Deanfield J
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S61-4. PubMed ID: 19675441
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.
    Colvine K; Kerr AJ; McLachlan A; Gow P; Kumar S; Ly J; Wiltshire C; Robinson E; Dalbeth N
    N Z Med J; 2008 Nov; 121(1285):73-81. PubMed ID: 19079439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.
    Filippi A; Paolini I; Innocenti F; Mazzaglia G; Battaggia A; Brignoli O
    J Hum Hypertens; 2009 Nov; 23(11):758-63. PubMed ID: 19242492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of guideline revisions on the process and outcome of hypertension management in general practice: a descriptive study.
    van der Wel M; Bakx C; de Grauw W; van Gerwen W; Mulder J; van Weel C
    Eur J Gen Pract; 2008; 14 Suppl 1():47-52. PubMed ID: 18949645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of recent trial results on cardiovascular risk management (Hatter Institute Cardiac Horizons series).
    Cardiovasc J Afr; 2008; 19(6):328-31. PubMed ID: 19104733
    [No Abstract]   [Full Text] [Related]  

  • 20. [From clinical observation to assessment of practices: guidelines for hypertension management].
    Bobrie G; Durieux P; Postel-Vinay N; Plouin PF; French Society of Nephrology
    Nephrol Ther; 2009 Jun; 5 Suppl 4():S240-5. PubMed ID: 19596342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.